$AXSM
Axsome Therapeutics, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021009924 Filed on March 01, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.25M $10.36M $7.240M
YoY Change 126.36% 98.47% 195.51%
% of Gross Profit
Research & Development $16.60M $17.38M $10.54M
YoY Change -39.7% -9.53% -4.18%
% of Gross Profit
Depreciation & Amortization $8.326K $0.00 $0.00
YoY Change 53.16% -100.0% -100.0%
% of Gross Profit
Operating Expenses $27.84M $27.74M $17.78M
YoY Change -14.3% 13.57% 32.2%
Operating Profit -$27.84M -$17.78M
YoY Change -14.3% 32.2%
Interest Expense -$1.420M -$1.470M -$550.0K
YoY Change -14300.0% 286.84% 77.42%
% of Operating Profit
Other Income/Expense, Net $50.00K
YoY Change
Pretax Income -$29.26M -$29.16M -$18.33M
YoY Change -9.91% 17.53% 33.21%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$29.26M -$29.16M -$18.33M
YoY Change -9.93% 17.57% 33.17%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$781.7K -$780.7K -$494.1K
COMMON SHARES
Basic Shares Outstanding 37.41M 37.34M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $164.7M $183.9M $190.7M
YoY Change -16.52% -16.41% 254.46%
Cash & Equivalents $164.7M $183.9M
Short-Term Investments
Other Short-Term Assets $400.0K $100.0K $100.0K
YoY Change 33.33% -75.0% -87.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $165.0M $184.0M $190.8M
YoY Change -16.48% -16.5% 249.49%
LONG-TERM ASSETS
Property, Plant & Equipment $74.32K $52.65K $30.42K
YoY Change 71.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $317.4K $317.4K $139.9K
YoY Change 217.38% 126.9% -30.06%
Total Long-Term Assets $1.868M $2.109M $170.3K
YoY Change 834.2% 1137.26% -14.85%
TOTAL ASSETS
Total Short-Term Assets $165.0M $184.0M $190.8M
Total Long-Term Assets $1.868M $2.109M $170.3K
Total Assets $166.9M $186.1M $191.0M
YoY Change -15.62% -15.6% 248.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.62M $13.50M $9.363M
YoY Change 19.85% 23.4% 53.5%
Accrued Expenses $7.100M $9.900M $7.100M
YoY Change -23.66% -9.17% 47.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $6.547M
YoY Change -100.0% 197.6%
Total Short-Term Liabilities $21.68M $23.44M $23.00M
YoY Change -16.92% -4.31% 75.59%
LONG-TERM LIABILITIES
Long-Term Debt $48.60M $48.32M $13.74M
YoY Change 213.54% 178.79% -21.01%
Other Long-Term Liabilities $300.0K $600.0K
YoY Change
Total Long-Term Liabilities $48.60M $48.32M $13.74M
YoY Change 213.54% 178.79% -21.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.68M $23.44M $23.00M
Total Long-Term Liabilities $48.60M $48.32M $13.74M
Total Liabilities $70.61M $72.34M $36.75M
YoY Change 69.74% 72.95% 20.48%
SHAREHOLDERS EQUITY
Retained Earnings -$308.1M -$278.8M -$226.7M
YoY Change 58.5%
Common Stock $404.3M $392.6M $3.726K
YoY Change 10.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $96.29M $113.8M $154.2M
YoY Change
Total Liabilities & Shareholders Equity $166.9M $186.1M $191.0M
YoY Change -15.62% -15.6% 248.52%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q2
OPERATING ACTIVITIES
Net Income -$29.26M -$29.16M -$18.33M
YoY Change -9.93% 17.57% 33.17%
Depreciation, Depletion And Amortization $8.326K $0.00 $0.00
YoY Change 53.16% -100.0% -100.0%
Cash From Operating Activities -$27.22M -$20.56M -$18.90M
YoY Change 16.94% 17.02% 117.74%
INVESTING ACTIVITIES
Capital Expenditures $30.00K -$20.00K $0.00
YoY Change 221.46% 100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$20.00K $0.00
YoY Change 221.46% 100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.116M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.029M 2.090M 12.27M
YoY Change 1174.96% -98.92% -38.12%
NET CHANGE
Cash From Operating Activities -27.22M -20.56M -18.90M
Cash From Investing Activities -30.00K -20.00K 0.000
Cash From Financing Activities 8.029M 2.090M 12.27M
Net Change In Cash -19.22M -18.49M -6.630M
YoY Change -15.17% -110.49% -159.52%
FREE CASH FLOW
Cash From Operating Activities -$27.22M -$20.56M -$18.90M
Capital Expenditures $30.00K -$20.00K $0.00
Free Cash Flow -$27.25M -$20.54M -$18.90M
YoY Change 17.02% 16.97% 117.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001579428
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020 axsm Cares Act Net Operating Loss Carryback Period
CARESActNetOperatingLossCarrybackPeriod
P5Y
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37635
CY2020 dei Entity Registrant Name
EntityRegistrantName
AXSOME THERAPEUTICS, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
22 Cortlandt Street
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
16th Floor
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
CY2020 dei City Area Code
CityAreaCode
212
CY2020 dei Local Phone Number
LocalPhoneNumber
332-3241
CY2020 dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
CY2020 dei Trading Symbol
TradingSymbol
AXSM
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37405268
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4241907
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70244579
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53647067
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28896749
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13598030
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9351522
CY2020 us-gaap Operating Expenses
OperatingExpenses
99141328
CY2019 us-gaap Operating Expenses
OperatingExpenses
67245097
CY2018 us-gaap Operating Expenses
OperatingExpenses
32846577
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-67245097
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-32846577
CY2018 us-gaap Investment Income Net
InvestmentIncomeNet
-1127305
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-102900600
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-68345186
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26883656
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7256080
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
251789
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2235878
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7105829
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78456569
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020Q2 dei Entity Public Float
EntityPublicFloat
2400000000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23495055
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-99141328
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
183876453
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
219966167
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
148373
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
413095
CY2020Q4 us-gaap Assets Current
AssetsCurrent
184024826
CY2019Q4 us-gaap Assets Current
AssetsCurrent
220379262
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52647
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30623
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1739475
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
317375
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
139875
CY2020Q4 us-gaap Assets
Assets
186134323
CY2019Q4 us-gaap Assets
Assets
220549760
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13504022
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10943325
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10949128
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1220587
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2602292
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23437858
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24494745
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17332626
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
581708
CY2020Q4 us-gaap Liabilities
Liabilities
72341414
CY2019Q4 us-gaap Liabilities
Liabilities
41827371
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37374088
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37374088
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36933217
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36933217
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3737
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
3693
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
392585265
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
354614189
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278796093
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175895493
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
-2565838
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
178722389
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
186134323
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220549760
CY2019 us-gaap Investment Income Net
InvestmentIncomeNet
-1239537
CY2020 axsm Income From Nyc Biotechnology Credit
IncomeFromNYCBiotechnologyCredit
53578
CY2019 axsm Income From Nyc Biotechnology Credit
IncomeFromNYCBiotechnologyCredit
139448
CY2018 axsm Income From Nyc Biotechnology Credit
IncomeFromNYCBiotechnologyCredit
217418
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2791000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-30965464
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.77
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37206928
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34020257
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
16717223
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1754974
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
380322
CY2018 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
131703
CY2018 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
37842
CY2018 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
12881321
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-30965464
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
937921
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6115160
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1143841
CY2019 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
249836
CY2019 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
387000
CY2019 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
238233817
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-68345186
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
178722389
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14756206
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1049849
CY2020 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
6
CY2020 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
884216
CY2020 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
14125506
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-102900600
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2020 us-gaap Profit Loss
ProfitLoss
-102900600
CY2019 us-gaap Profit Loss
ProfitLoss
-68345186
CY2018 us-gaap Profit Loss
ProfitLoss
-30965464
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
14756206
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6115160
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1754974
CY2020 axsm Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
7155337
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
786750
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
649993
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
375635
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
53854
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2791000
CY2020 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
8967
CY2020 us-gaap Depreciation
Depreciation
23864
CY2019 us-gaap Depreciation
Depreciation
37330
CY2018 us-gaap Depreciation
Depreciation
48935
CY2020 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-264722
CY2019 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-833265
CY2018 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-32058
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
177500
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
27530
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-75607
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2560697
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1163765
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46375059
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30053701
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45891
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16121
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32696
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45891
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16121
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32696
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
50000000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
20000000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1102609
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
25997
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
21660000
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
7238889
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3333333
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14125506
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
238233817
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12881321
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
249836
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
131703
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1049849
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1143841
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
380322
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42412746
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
252388605
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10034016
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36089714
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
205997425
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20052381
CY2019Q4 us-gaap Cash
Cash
219966167
CY2018Q4 us-gaap Cash
Cash
13968742
CY2017Q4 us-gaap Cash
Cash
34021123
CY2020Q4 us-gaap Cash
Cash
183876453
CY2019Q4 us-gaap Cash
Cash
219966167
CY2018Q4 us-gaap Cash
Cash
13968742
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2097292
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1287506
CY2018 us-gaap Interest Paid Net
InterestPaidNet
771966
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1793328
CY2020 axsm Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
884216
CY2019 axsm Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
387000
CY2018 axsm Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
37842
CY2020Q4 axsm Number Of Late Stage Product Candidates
NumberOfLateStageProductCandidates
5
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278800000
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At December 31, 2020, the majority of the Company’s cash was held by one financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</p>
CY2020Q4 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.41%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</p>
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
183900000
CY2020 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
266668
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2017Q4 axsm Fair Value Of Warrants
FairValueOfWarrants
2791000
CY2017Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2018-12-11
CY2018Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2019Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-102900600
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-68345186
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-30965464
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37206928
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34020257
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
436567
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26883656
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.77
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3885524
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3528103
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2414200
CY2020Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4293522
CY2019Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8209594
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2870261
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2056356
CY2020Q4 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1155508
CY2019Q4 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
554011
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
393958
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
129167
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10949128
CY2020 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2362083
CY2019 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1362500
CY2018 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
751670
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
469676
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2020Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
151912
CY2019Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
404364
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1830064
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
405071
CY2019Q4 axsm Long Term Debt Current Net Of Noncurrent Debt Discount
LongTermDebtCurrentNetOfNoncurrentDebtDiscount
2666667
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17332626
CY2019Q4 axsm Long Term Debt Current Net Of Noncurrent Debt Discount
LongTermDebtCurrentNetOfNoncurrentDebtDiscount
2666667
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
64375
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2602292
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
12193153
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
19761468
CY2020Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
18045379
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In June 2020, the company entered into a lease for office space at 22 Cortlandt St, New York, NY consisting of the 16th floor which began on August 1, 2020. The term for this lease was to expire on July 31, 2021. At lease inception the lease arrangement was deemed to be a short-term lease due to its term not exceeding one year, and as such was accounted for on a straight-line basis until December 2020.
CY2020Q2 axsm Lease Commencement Date
LeaseCommencementDate
2020-08-01
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2020 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extend through July 31, 2022
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
870275
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
485548
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
315301
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1739475
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1220587
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
581708
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1802295
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.03
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
47821
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1250000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
630000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1880000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
77705
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1802295
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2017Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9500000
CY2017Q4 us-gaap Share Price
SharePrice
5.325
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1783587
CY2017Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9500000
CY2017Q4 axsm Stock Issued During Period Value New Issues Net
StockIssuedDuringPeriodValueNewIssuesNet
8800000
CY2017Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
745856
CY2020 axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3458447
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.19
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
649142
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
54.50
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
127778
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.22
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
207628
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
35.85
CY2020 axsm Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
38267
CY2020 axsm Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
58.98
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3733916
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
243556917
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3727747
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
16.36
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
243062340
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2479110
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.66
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
175575360
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
123037
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
36.77
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.49
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
20900000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
10716
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9400000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4500000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
500000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14756206
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6115160
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1754974
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2099199
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.21
CY2018 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
15750
CY2018 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
3.06
CY2018 axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
101310
CY2018 axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
1.30
CY2018 axsm Warrants Expired In Period
WarrantsExpiredInPeriod
1890602
CY2018 axsm Warrants Expired In Period Weighted Average Exercise Price
WarrantsExpiredInPeriodWeightedAverageExercisePrice
5.33
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
249000000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
52329877
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
32299085
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
86829
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
59557
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.35
CY2019 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
58334
CY2019 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
8.10
CY2019 axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
111715
CY2019 axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
6.73
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
69656
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.21
CY2020 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
15541
CY2020 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
80.43
CY2020 axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
69656
CY2020 axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
7.21
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
CY2017Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2018-12-11
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
32410604
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
20000317
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
7329228
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
3485519
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
13028222
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10366683
CY2020Q4 axsm Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
1765452
CY2019Q4 axsm Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
985431
CY2020Q4 axsm Deferred Tax Assets Charitable Contribution
DeferredTaxAssetsCharitableContribution
5408
CY2019Q4 axsm Deferred Tax Assets Charitable Contribution
DeferredTaxAssetsCharitableContribution
5408
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
7883
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
11401
CY2020Q4 axsm Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
612973
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
968709
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1200754
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
108545185
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68414155
CY2019Q4 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
121875
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
591607
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
32491457
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
17778834
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21126801
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
27744236
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
591607
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
121875
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
107953578
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
68292280
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
39700000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
27000000.0
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12500000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.137
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.135
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.131
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.018
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.012
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.011
CY2020 axsm Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.006
CY2019 axsm Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.001
CY2018 axsm Effective Income Tax Rate Reconciliation Permanent Differences Percent
EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
-0.013
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.025
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.042
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.063
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.384
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.398
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.402
CY2020 axsm Tax Cuts And Jobs Act Net Operating Loss Carryovers And Carry Backs Offset Percentage
TaxCutsAndJobsActNetOperatingLossCarryoversAndCarryBacksOffsetPercentage
1
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-32484146
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18326992
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22924815
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-29164647
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
10421473
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-19135612
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-24806984
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
13448219
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
18947235
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
24428170
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-10640376
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-13762214
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71

Files In Submission

Name View Source Status
0001564590-21-009924-index-headers.html Edgar Link pending
0001564590-21-009924-index.html Edgar Link pending
0001564590-21-009924.txt Edgar Link pending
0001564590-21-009924-xbrl.zip Edgar Link pending
axsm-10k_20201231.htm Edgar Link pending
axsm-10k_20201231_htm.xml Edgar Link completed
axsm-20201231.xsd Edgar Link pending
axsm-20201231_cal.xml Edgar Link unprocessable
axsm-20201231_def.xml Edgar Link unprocessable
axsm-20201231_lab.xml Edgar Link unprocessable
axsm-20201231_pre.xml Edgar Link unprocessable
axsm-ex231_120.htm Edgar Link pending
axsm-ex311_64.htm Edgar Link pending
axsm-ex312_65.htm Edgar Link pending
axsm-ex321_62.htm Edgar Link pending
axsm-ex322_63.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4vlmlsfrvek000001.jpg Edgar Link pending
g4vlmlsfrvek000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending